Why the study?
Does stopping mineralocorticoid receptor antagonists after an episode of hyperkalaemia reduce recurrent hyperkalaemia or increase death or cardiovascular events?
Does stopping mineralocorticoid receptor antagonists after an episode of hyperkalaemia reduce recurrent hyperkalaemia or increase death or cardiovascular events?
Stopping MRA therapy after an episode of hyperkalaemia reduces the risk of recurrent hyperkalaemia but is associated with a higher risk of death or cardiovascular events.
Answers are grounded in this paper and cite their sources.
Caution against stopping MRA after hyperkalaemia; leaves open optimal management pending randomized trials.
Stopping MRA after an episode of hyperkalaemia was associated with reduced risk for recurrent hyperkalaemia, but higher risk of death or cardiovascular events. Recurrent hyperkalaemia was common in either strategy.
No takes yet. Share an insight, caveat, or question.
Trevisan et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: